Bisphosphonates and their indication to prevent bone density loss in cancer therapy
DOI:
https://doi.org/10.33448/rsd-v11i4.21577Keywords:
Osteoporotic fractures; Osteoporosis; Fractures, closed; Bone density conservation.Abstract
Aim: To establish a protocol for patients medicated with bisphosphonates, through literature review, to avoid osteonecrosis and to provide professional guidance to accomplish the appropriate treatment. Methodology: On line searches were accomplished for the construction of this paper, which included as databases Web of Science, PUBMED Central, BVS/BIREME, Science Direct, The Cochrane Library and also PROSPERO. Results: The following characteristics were observed in the research of this protocol: Drugs with antireabsorption properties, RANK-L Inhibitor, Antiangiogenic agents, Clinical Manifestations, Drug-related risk factors, Local risk factors to be observed, Systemic and demographic risk factors, High risk factors considered. Conclusions: Bisphosphonates may be a helpful therapy for patients with organic consequences related to the therapy applied with them. Appropriate anamnesis and assessment of the systemic conditions for patients using them are mandatory requirements before their prescription.
References
Abtahi J., Agholme F., Aspenberg P. (2013). Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. International Journal Oral Maxillofacial Surgery, v. 5, n. 42, p. 632- 636.
Badros A. (2006). Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology, 24(6), 945-952.
Beech N., Robinson S., Batstone M. (2014). Dental management of patients irradiated for head and neck cancer. Australian Dental Journal, 59(1), 20-28. https://doi.org/10.1111/adj.12134
Carter, G. D., Goss, A. N. (2003) Bisphosphonates and avascular necrosis of the jaws. Australian Dental Journal, 48(8), 268.
Choudhary M., Ahmed AA., Williamson JG (2003). Sole bladder metastasis from breast cancer. Journal of Obstetrics and Gynaecology, 23(2), 212.
Cranney A., Waldegger L., Zytaruk N., Shea B., Weaver B., Papaioannou A., Robinson V., Wells G., Tugwell P., Adachi JD., Guyatt G. (2004) Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database of Systematic Reviews, 2(7), 254. Doi: 10.1002/14651858.CD004523.
Delanian S., Depondt J., Lefaix JL. (2005). Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head & Neck – Wiley Online Library, 27(3), 114–123.
Eid A., Atlas J. (2014). The role of bisphosphonates in medical oncology and their association with jaw bone necrosis. Oral Maxillofacial Surgery Clinics of North America, 26 (5), 231-237.
Eriksen EF., Díez-Pérez A., Boonen S. (2014). Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 58, 126–35. doi:10.1016/j.bone.2013.09.023.
Gauthier K., Bai A., Perras C., Cunningham J., Ahuja T., Richter T., Kovacs C. (2012). Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis: Clinical Effectiveness and Harms. Rapid Response Report: Systematic Review. PMID 24278999.
Gracis S. (2013) Prosthetic and biomechanical factors affecting bone remodeling around implants. The European Journal of Esthetic Dentistry, 8 (2), 313-314.
Hewitt C., Farah CS. (2007) Bisphosphonate – related osteonecrosis of the jaws: a comprehensive review. Journal of Oral Pathology & Medicine, 36 (4), 319-328.
Allen CS., Yeung JH., Vandermeer B., Homik J. (2004). Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews, 2 (4), 20. Doi: 10.1002/14651858.CD001347.pub2.
Hutchinson M., O´Ryan F., Chavez V., Lathon PV., Sanchez G., Hatcher SDC., Indresano AT., Lo JC. (2010). Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. Journal of Oral and Maxillofacial Surgery, 68 (9), 2232–2240. Doi: 10.1016/j.joms.2010.05.003.
Iyer, S., Balasubramanian, D. (2012). Management of radiation wounds. Indian Journal of Plastic Surgery, 45 (2), 325-331.
Key, J. E., Rahemtulla, F. G., Eleazer, P. D. (2006). Citotoxicity of a new root canal filling material on human gingival fibroblasts. Journal of Endodontics, 32 (8), 756-758.
Khosla, S. (2007). Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 22 (10), 1479–1491.
Martins, M. A. T., Giglio, M., Martins, M. D., Pavesi, V. C. S., Lascala, C. A. (2009). Osteonecrose dos maxilares associada ao uso de bisfosfonatos: importante complicação do tratamento oncológico. Revista Brasileira de Hematologia e Hemoterapia, 31, (1), 41-46.
Maruotti ,N. (2012). Bisphosphonates: Effects on osteoblast. European Journal of Clinical Pharmacology, 68 (7),. 1013–1018.
Mawardi ,H. (2009). Sinus tracts – an early sign of bisphosphonate-associated osteonecrosis of the jaws? Journal Oral and Maxillofacial Surgery, 67, (8), 593-601.
Migliorati, C. A. (2005). Managing he care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. The Journal of the American Dental Association, 136 (12), 1658-1668.
Nair, P. N. R. (2007). Falhas endodônticas: a patobiologia da periodontite apical pós-tratamento. In: Cohen S, Hargreaves KM. Caminhos da polpa. 9ª edição. Rio de Janeiro: Mosby. 918-43.
Otto, S. (2015). Osteonecroses maxilar associada a fármacos. Quintessence Internacional, 3 (2), 88-95.
Papapoulos, S. E., Cremers SC. (2007). Prolonged bisphosphonate release after treatment in children. The New England Journal of Medicine, 356, (10), 1075-1076.
Ruggiero, S. L. (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate related osteonecroses of the jaws 2009 update. Journal Oral and Maxillofacial Surgery, 2, (67), 2-12.
Ruggiero, T. (2014). Position Paper. American Association of Oral and Maxillofacial Surgery, 72 (10), 1938- 1940.
Ruggiero, S. L. (2014). Associação Americana Cirurgiões de Cirurgia Oral e Maxilofacial osteonecrose relacionada à medicação da mandíbula - atualização de 2014. Journal of Oral and Maxillofacial Surgery, 72 (10). 1938-1956.
Santos-Silva, A. R. (2013). Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 115 (4), 32-36.
Salvatore, L. (2014). American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw – 2014 Update. Journal of Oral Maxillofacial Surgery, 72 (10), 1938-1956.
Scully, C. (2013). Osteonecrosis mandibular relacionada con bifosfonatos. Diagnóstico diferencial por localización. LA Moreno López. Guía de Bolsillo de Enfermadades Orales 1. España: Elsevier, 157-328.
Serrano, A. J., Begoña, L., Anitua, E., Cobos, R., Orive, G. (2013). Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol.Endocrinol. 29 (12): 1005–14. doi:10.3109/09513590.2013.813468. PMID 24063695. S2CID 20163452.
Sivolella, S. (2013). Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Research, 33, (1), 1793-7.
Sjögren ,U., Sundgvist G., Nair P. N. R. Tisue reaction to guttapercha of various sizes when implanted subcutaneously in guinea pigs. European Journal of Oral Sciences,103 (5), 313-21.
Tarassoff P., Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. Journal Oral Maxillofacial Surgery, 61, (21), 1238-1239.
Tardasta A. (2015). Bisphosphonate associated osteomyelitis of the jaw in patients with bony exposure: prevention, a new way of thinking. Journal of Applied Oral Science, 23, (3), 310-11.
Tortora GJ., Funke BR., Case CL. (2000). Microbiologia. 6. ed. Porto Alegre: Artmed, 826-7.
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack R. P., Petak, S. M. (2010). American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 16, 1–37. doi:10.4158/ep.16.s3.1. PMC 4876714. PMID 21224201.
Woo, S., Hellstein J., Kalmar J. (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws (PDF). Ann Intern Med. 144 (10): 753–61. doi:10.7326/0003-4819-144-10-200605160-00009. PMID 16702591. S2CID 53091343.
Yoneda, T. (2017). Antiresorptive agent-related osteonecrosis of the jaws: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Journal of Bone and Mineral Metabolism, 35 (4), 6-19.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Kelma Lais de Aguiar Martins de Oliveira; Luciano Barreto Silva; Guilherme Marinho Sampaio; Rodolfo Scavuzzi Carneiro Cunha; Alexandrino Pereira dos Santos Neto; Felipe Leonardo de Melo Almeida Fonseca; Eudoro de Queiroz Marques Filho; William José Lopes Freitas; Ailton Coelho de Ataíde Filho; Sandra Sayão Maia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
